Latest News, Press Releases & Events

Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis

DURHAM, N.C., October 18, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe respiratory diseases, today announced the first patient was dosed in the HOPE-1 study, a multinational Phase 2 clinical trial for its lead compound, SPX-101 in cystic fibrosis (CF). HOPE-1 is a 28-day study using an adaptive […]

Continue Reading

Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference

-No dose-limiting adverse effects in 14-day multiple ascending dose study -The Company to receive up to total of $5 million to support Phase 2 trial DURHAM, N.C., June 20, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, announced today that Cystic Fibrosis Foundation Therapeutics (CFFT), […]

Continue Reading

Spyryx Biosciences to Present at the 2017 Bio International Convention

DURHAM, N.C., June 16, 2017 - Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that President and Chief Executive Officer, John Taylor, will present a corporate overview at the 2017 BIO International Convention at the San Diego Convention Center in San Diego, California, on Tuesday, [...]
Continue Reading